RTTNews | Jul 30, 2021 09:14AM EDT

09:13 Friday, July 30, 2021 (RTTNews.com) - Cyclo Therapeutics Inc. (CYTH) announced new positive safety and efficacy data from ongoing phase 1 open-label extension study of trappsol cyclo for the treatment of niemann-pick disease type C1 or NPC. NPC is a rare, progressive and fatal genetic disorder characterized by abnormal accumulation of cholesterol in cells.

The data provide additional support for the capacity of Trappsol Cyclo to stabilize disease progression with home-based intravenous infusions in Niemann-Pick Disease Type C1, the company said in a statement.

Trappsol Cyclo is currently being evaluated in the pivotal Phase 3 study, TransportNPC, for the treatment of NPC1. Cyclo Therapeutics received Orphan Drug Designation for Trappsol Cyclo to treat NPC1 in both the US and EU and Fast Track and Rare Pediatric Disease Designations in the US.

Read the original article on RTTNews ( https://www.rttnews.com/3214264/cyclo-therapeutics-reports-positive-data-from-phase-1-study-on-trappsol-cyclo-for-npc-treatment.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved